AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03012893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound transverse scan
Description: Linear transducer will be placed at patient's lateral neck using transverse scan. The unique characteristic of sonography of transvers process of C6 and C7 will be used to identify the transverse process of C6 and C7. C6 transverse process has a very prominence anterior tubercle (known as Chassaignac tubercle). While anterior tubercle of C7 is absent. After identifying the C7 transverse process, simultaneously the color Doppler mode will be activated to identify the vertebral artery for double confirmation.
Study NCT01253512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-18
Description: A single 0.25 or 0.5 mg/kg of THR-18 in combination with tPA treatment.
Study NCT03298113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cavilon Advanced Skin Protectant
Description: Applicator contains a polymeric-cyanoacrylate solution intended to cover and protect intact or damaged skin. Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier.
Study NCT03298113 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IAD Hospital Standard Care
Description: Devices such as local skin protectants will be used according to the hospital IAD care regime and under consideration of the respective manufacturers' instructions for use.
Study NCT03618472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride 850 MG
Description: Regular strength metformin (850 mg/tab)
Study NCT03618472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Starch based placebo manufatured to mimic Metformin 850 mg
Study NCT03966716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthroplasty
Description: Patients with an undisplaced femoral neck fracture receive a hemi or total hip arthroplasty depending on each hospital's routine for patient age and mobility.
Study NCT03966716 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Fixation
Description: Patients with an undisplaced femoral neck fracture undergo a closed reduction and internal fixation with 2-3 screws or pins, or sliding hip screw device. Type of fixation depends on each hospital's routine.
Study NCT03669042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PhotoFix
Description: PhotoFix Patch Implantation
Study NCT01253512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous
Study NCT01597622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: 10 mg/kg administered intravenously over 1 hour every 4 weeks
Study NCT03588481 — intervention group
Intervention type: DEVICE
Intervention: DESyne X2
Description: Novolimus-eluting stent
Study NCT05007093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: If intolerance occurs, the dose can be downregulated
Study NCT01933711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT03310710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viabahn BX stent
Description: Viabahn BX stent graft used as the branch device with a fenestrated EVAR graft
Study NCT03012893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopic technique
Description: C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
Study NCT03693950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-066
Description: BCD-066 will be administered once a week intravenously in a dose 1 µg/kg
Study NCT03693950 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aranesp
Description: Aranesp will be administered once a week intravenously in a dose 1 µg/kg
Study NCT03079427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin
Description: Gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 Day 1 and 8, every 3 weeks
Study NCT03079427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1,250 mg/m2 Day 1 to 14, every 3 weeks
Study NCT03749733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Reference Product)
Description: Marketed Drug
Study NCT03749733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Test Product)
Description: Investigational Medicinal Product
Study NCT03082651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating run training load
Description: Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period
Study NCT03082651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating footwear
Description: Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.
Study NCT03082651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant training
Description: Runners will be assigned identical training sessions over a 7-day period.
Study NCT03082651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constant training
Description: Runners will be assigned identical training sessions over a 7-day period.
Study NCT03082651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant footwear
Description: Runners perform runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
Study NCT01564329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endostar
Description: Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous drip, Day 6; Carboplatin AUC=5,intravenous drip, Day 6; 21 days as a cycle, 4 cycles in all.
Study NCT03082651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constant footwear
Description: Runners perform runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
Study NCT02752334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: Magnesium has antinociceptive effects in animal and human models, principally related to blocking the N-methyl-D-aspartate (NMDA) receptors and regulation of calcium influx into cells.
Study NCT02528409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Medication currently approved for major depression.
Study NCT02528409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03971734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson 0.05mg
Description: Regadensoson 0.05mg administered prior to MRI
Study NCT03971734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadensoson 0.1mg
Description: Regadensoson 0.1mg administered prior to MRI
Study NCT03971734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadensoson 0.2mg
Description: Regadensoson 0.2mg administered prior to MRI
Study NCT03971734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadensoson 0.4mg
Description: Regadensoson 0.4mg administered prior to MRI
Study NCT03971734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadensoson 0.7mg
Description: Regadensoson 0.7mg administered prior to MRI
Study NCT03971734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadensoson 1.0mg
Description: Regadensoson 1.0mg administered prior to MRI
Study NCT03971734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadensoson 1.4mg
Description: Regadensoson 1.4mg administered prior to MRI
Study NCT04502706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0189
Description: GS-0189 will be administered intravenously.
Study NCT04502706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered intravenously.
Study NCT00954603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: 25-100 mg
Study NCT00954603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol
Description: 0.5-2 mg
Study NCT03888534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib intravenous injection in combination with reduction chemotherapy.
Study NCT01898234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revaclear
Description: Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
Study NCT01898234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helixone high flux
Description: Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
Study NCT02515643 — intervention group
Intervention type: OTHER
Intervention: Endothelial dysfunction
Description: One month before surgery and one year after, the following procedures will be performed in donors and recipients:~1. Blood samples will be obtained for the measurement of endothelial dysfunction and low grade inflammation markers.~2. Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness, carotid-femoral pulse wave velocity (m/s) will be performed by pulse tonometry.~3. Ambulatory blood pressure monitoring with overnight-automated ABPM monitor~4. Estimation of glomerular filtration rate by Iohexol method
Study NCT01898234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xevonta
Description: Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
Study NCT01898234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helixone low flux
Description: Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
Study NCT00926367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin and benzoyl peroxide
Description: Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide gel. This contains a topical antibiotic and benzoyl peroxide gel.
Study NCT00926367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzoyl peroxide 2.5% and adapalene 0.1% gel
Description: Once-daily applications, to the randomized side of the face either left or right,benzoyl peroxide and adapalene gel
Study NCT02414763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teachable Moment Brief Intervention
Description: functional analysis, collaborative interpersonal style
Study NCT03815643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants entering this roll over study will receive avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2 weeks until progressive disease, according to respective parent studies (EMR100070-001, EMR100070-002, EMR100070-004 and EMR100070-008).
Study NCT01242228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral
Study NCT01242228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor
Description: oral
Study NCT01427322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: given orally 2-4 hours before first fraction of radiation therapy
Study NCT01427322 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Standard radiation therapy
Study NCT01427322 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Standard radiation therapy
Study NCT00869427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin C
Description: vitamin C 1g bid for 1 year
Study NCT03031535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal octreotide acetate
Description: Intranasal spray of octreotide acetate
Study NCT00468338 — intervention group
Intervention type: DEVICE
Intervention: BIS monitor
Description: BIS monitor measures the depth of anesthesia and was used in the entire group
Study NCT03031535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide acetate
Description: Subcutaneous injectable solution of octreotide acetate
Study NCT03031535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Growth hormone-releasing hormone
Description: Part of the well established GHRH/Arginine challenge to detect GH deficiency.
Study NCT03031535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Arginine hydrochloride
Description: Part of the well established GHRH/Arginine challenge to detect GH deficiency.
Study NCT01869725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gallium Ga 68-edotreotide
Description: Given IV
Study NCT01869725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography
Description: Undergo gallium Ga 68-edotreotide PET/CT scan
Study NCT01869725 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: indium In 111 pentetreotide
Description: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
Study NCT03356132 — intervention group
Intervention type: DEVICE
Intervention: Silimed® Textured Silicone Gel-Filled Breast Implant
Description: Women undergoing primary and secondary breast augmentation using Silimed® Textured Silicone Gel-Filled Breast Implant.
Study NCT03356132 — intervention group
Intervention type: DEVICE
Intervention: Silimed® Polyurethane Foam Covered Silicone Gel-Filled Breast Implant
Description: Women undergoing primary and secondary breast augmentation using Silimed® silicone gel-filled breast implants with polyurethane foam covered surface.
Study NCT01869725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo indium In 111 pentetreotide contrast-enhanced CT scan
Study NCT01869725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: contrast-enhanced magnetic resonance imaging
Description: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
Study NCT00950911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amg 162
Description: 120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.
Study NCT02521766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmoni Modular Intraocular Lens
Description: Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
Study NCT03282123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine
Description: 80 to 120 mg MDMA
Study NCT03282123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manualized therapy
Description: Non-directive therapy conducted during MDMA-assisted therapy session
Study NCT04004000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod
Description: The main study includes a treatment period of approximately one year. Subjects will receive 15 mg of losmapimod twice daily by mouth; for a total of 30 mg daily. The study drug should be taken with food and the date and time of each dose taken recorded in the subject diary.~Only subjects who participated in and completed all procedures for the main study (Week 60) will be eligible to participate in the extension.~For the extension, subjects will receive 15 mg of losmapimod by mouth twice daily for a total of 30 mg by mouth daily. Participation will continue until 90 days after commercial drug is available post regulatory approval or study termination.
Study NCT01398839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VEGA UV-A Illumination System
Description: Only subjects assigned to the treatment group will receive treatment with the UV Light
Study NCT01398839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Both treatment and sham groups will receive riboflavin
Study NCT01398839 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Riboflavin
Description: Both treatment and sham groups will receive riboflavin
Study NCT04306172 — intervention group
Intervention type: OTHER
Intervention: An US Readmission Risk Prediction Model
Description: Logistic regression model that predicts the risk of all-cause unplanned readmissions developed by the privately held healthcare software company EPIC.
Study NCT02521766 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Commercially Available Intraocular Lens
Description: IOL per investigator's standard of care
Study NCT02521766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optic exchange
Description: Removal of one optic and replacement with another for the purpose of improving refractive outcomes
Study NCT04708600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pitch Elevation Therapy
Description: Goal: mean fundamental frequency of 180Hz (range 140 and 300Hz); Doses and duration: 5 one hour sessions (5h), 5 weeks~Content:~* auditory discrimination of lower and higher tones~* pitch glides~* pitch glides using straw phonation and resonance tube phonation~* practice of higher pitch voice (target: 180Hz) in isolated vowels - syllables - mono and bisyllabic words -phrases - sentences and texts - conversation (generalization to spontaneous speech)
Study NCT03316456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Observational: Stool Sample Collection
Description: Observational: Stool Sample Collection~- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner.
Study NCT03316456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Observational: Blood Sample Collection
Description: Observational: Blood Sample Collection~- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner.
Study NCT03316456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Observational: Urine Sample Collection
Description: Observational: Urine Sample Collection~- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner.
Study NCT04523181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antroquinonol
Description: double-blind for antroquinonol and Placebo with same out-look and same frequency.
Study NCT04523181 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule without active compound
Study NCT02998489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast milk advancement
Description: 30-40 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
Study NCT02998489 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional milk advancement
Description: 20 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
Study NCT02755922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Application of autologous mesenchymal stem cells
Description: within the surgical procedure, mesenchymal stem cells, were applied on the fracture site. Imaging by X-ray and CT and imaging analysis was done after fracture repair, at week 4 and week 12
Study NCT00928200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: The dose of Erwinase will be assigned at study entry. The first dose of Erwinase wil be given between Days 3-5 and will continue on a M-W-F schedule for a total of 10 doses.~Erwinase will be administered as a 2-hour intravenous infusion.
Study NCT00928200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22
Study NCT00928200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg/m2/day divided BID. Give by mouth days 1-14.
Study NCT00928200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2/day IV over 15 minutes on day 1
Study NCT00928200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given Intrathecally at the dose defined by age on day 1. 30 mg for age 1-1.99 50 mg for age 2-2.99 70 mg for age 3 and older
Study NCT00928200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given Intrathecally to all patients who are CNS 1 or 2 at study entry. Dose defined by age. Given on day 15 8mg for age 1-1.99 10 mg for age 2-2.99 12 mg for age 3-8.99 15 mg for age 9 and older
Study NCT00928200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Intrathecal Therapy
Description: Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS 3 at study entry. Doses determined by age.